[A26-81] Ivosidenib (acute myeloid leukaemia) – Addendum to Project A26-19
Last updated 20.08.2026
Project no.:
A26-81
Commission:
Commission awarded on 07.07.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Adults with newly diagnosed acute myeloid leukaemia with an isocitrate dehydrogenase-1 R132 mutation for whom standard induction chemotherapy is not suitable
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
https://doi.org/10.60584/A26-81
| Project no. | Title | Status |
|---|---|---|
| A26-19 | Ivosidenib (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
20-08-2026 A G-BA decision was published.
G-BA documents on this decision